Loading viewer...
conference
Format: PDF conference
Nektar Therapeutics presented at Cowen & Company's 37th Annual Healthcare Conference in March 2017, highlighting its biopharmaceutical pipeline including ONZEALD for metastatic breast cancer, NKTR-181 abuse-deterrent opioid, and NKTR-214 IL-15 agonist. The company outlined integrated R&D capabilities across facilities in San Francisco, Huntsville, and Hyderabad, with projected revenue of $375-450M annually by 2021 from its partnered portfolio.
investor_presentation
31 Pages
conference
37 Pages
Sitio Royalties
Calumet Specialty Products 2023 Wells Fargo Midstream Utilities
conferenceconference
20 Pages
Calumet Specialty Products Partners
Nexstar Media Group 2016 Communacopia Conference
conferenceconference
13 Pages
Nexstar Media Group
NASA Small Satellite Systems Engineering Webinar Series 2024
conferenceconference
18 Pages
National Aeronautics and Space Administration (NASA)